NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer

Lancet Oncol. 2016 Oct;17(10):1357-1358. doi: 10.1016/S1470-2045(16)30435-1. Epub 2016 Aug 23.

Authors

Caroline J Hall¹, Nwamaka Umeweni², Helen Knight², Lindsay Smith²

Affiliations

¹ National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT, UK. Electronic address: [email protected].
² National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT, UK.

PMID: 27567055
DOI: 10.1016/S1470-2045(16)30435-1

No abstract available

Publication types

News

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / genetics
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / economics
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / secondary
Cost-Benefit Analysis
Drug Approval
Drug Costs
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / mortality
Lung Neoplasms / pathology
Practice Guidelines as Topic
Ramucirumab
Treatment Outcome
United Kingdom

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological